Extended high viremics: A substantial fraction of individuals maintain high plasma viral RNA levels after acute HIV-1 subtype C infection

AIDS

Volumn 25, Issue 12, 2011, Pages 1515-1522

  Novitsky, Vladimir ^a,b   Ndung'U, Thumbi ^c,d   Wang, Rui ^a   Bussmann, Hermann ^a,b   Chonco, Fundisiwe ^c   Makhema, Joseph ^a,b   De Gruttola, Victor ^a   Walker, Bruce D ^d,e,f   Essex, M ^a,b  

^a Harvard AIDS Institute   (United States)

^b BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

HIV 1 subtype C; HIV 1 transmission; primary infection; southern Africa; viral HIV 1 RNA load

Indexed keywords

VIRUS RNA;

ARTICLE; BOTSWANA; CD4 LYMPHOCYTE COUNT; DISEASE DURATION; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; PATIENT IDENTIFICATION; PRIORITY JOURNAL; SOUTH AFRICA; T CELL DEPLETION; VIRUS LOAD;

EID: 85027958165     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283471eb2     Document Type: Article

References (35)

1. Kaufmann GR, Cunningham P, Kelleher AD, Zaunders J, Carr A, Vizzard J, et al. Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. The Sydney Primary HIV Infection Study Group. J Infect Dis 1998; 178: 1812-1815. (Pubitemid 28558161)
2. Kaufmann GR, Duncombe C, Zaunders J, Cunningham P, Cooper D. Primary HIV-1 infection: a review of clinical manifestations, immunologic and virologic changes. AIDS Patient Care STDS 1998; 12:759-767. (Pubitemid 28487710)
3. Little SJ, McLean AR, Spina CA, Richman DD, Havlir DV. Viral dynamics of acute HIV-1 infection. J Exp Med 1999; 190:841-850. (Pubitemid 29451629)
4. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17:1871-1879. (Pubitemid 37070272)
5. Schacker TW, Hughes JP, Shea T, Coombs RW, Corey L. Biological and virologic characteristics of primary HIV infection. Ann Intern Med 1998; 128:613-620. (Pubitemid 28169637)
6. Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 1991; 324:961-964.
7. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-1170. (Pubitemid 26001148)
8. Mellors JW, Kingsley LA, Rinaldo CRJ, Todd JA, Hoo BS, Kokka RP, Gupta P. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122:573-579.
9. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4R lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-954. (Pubitemid 27255797)
10. Clark S, Saag M, Decker W, Campbell-Hill S, Roberson J, Veldkamp P, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 1991; 324:954-960.
11. Kassutto S, Maghsoudi K, Johnston MN, Robbins GK, Burgett NC, Sax PE, et al. Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection. Clin Infect Dis 2006; 42:1024-1031.
12. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med 1998; 339:33-39.
13. de Wolf F, Spijkerman I, Schellekens PT, Langendam M, Kuiken C, Bakker M, et al. AIDS prognosis based on HIV-1 RNA, CD4R T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS 1997; 11:1799-1806. (Pubitemid 27500955)
14. Lavreys L, Baeten JM, Overbaugh J, Panteleeff DD, Chohan BH, Richardson BA, et al. Virus load during primary human immunodeficiency virus (HIV) type 1 infection is related to the severity of acute HIV illness in Kenyan women. Clin Infect Dis 2002; 35:77-81. (Pubitemid 34666863)
15. Pilcher CD, Price MA, Hoffman IF, Galvin S, Martinson FE, Kazembe PN, et al. Frequent detection of acute primary HIV infection in men in Malawi. AIDS 2004; 18:517-524. (Pubitemid 38365880)
16. Dyer JR, Kazembe P, Vernazza PL, Gilliam BL, Maida M, Zimba D, et al. High levels of human immunodeficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa. J Infect Dis 1998; 177:1742-1746. (Pubitemid 28243608)
17. Novitsky V, Woldegabriel E, Kebaabetswe L, Rossenkhan R, Mlotshwa B, Bonney C, et al. Viral load and CD4R T cell dynamics in primary HIV-1 subtype C infection. J Acquir Immune Defic Syndr 2009; 50:65-76.
18. Ball SC, Abraha A, Collins KR, Marozsan AJ, Baird H, Quinones-Mateu ME, et al. Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J Virol 2003; 77:1021-1038. (Pubitemid 36055524)
19. Abraha A, Nankya IL, Gibson R, Demers K, Tebit DM, Johnston E, et al. CCR5-and CXCR4-tropic subtype C HIV-1 isolates have lower pathogenic fitness as compared to the other dominant group M subtypes: implications for the epidemic. J Virol 2009; 83:5592-5605.
20. Fideli US, Allen SA, Musonda R, Trask S, Hahn BH, Weiss H, et al. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses 2001; 17:901-910. (Pubitemid 32881333)
21. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-929. (Pubitemid 30177052)
22. Lingappa JR, Hughes JP, Wang RS, Baeten JM, Celum C, Gray GE, et al. Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One 2010; 5:e12598.
23. Hisada M, O'Brien TR, Rosenberg PS, Goedert JJ. Virus load and risk of heterosexual transmission of human immunodeficiency virus and hepatitis C virus by men with hemophilia. The Multicenter Hemophilia Cohort Study. J Infect Dis 2000; 181:1475-1478. (Pubitemid 30252559)
24. Tovanabutra S, Robison V, Wongtrakul J, Sennum S, Suriyanon V, Kingkeow D, et al. Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr 2002; 29:275-283. (Pubitemid 34208536)
25. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1403-1409. (Pubitemid 40563350)
26. Celum CL, Buchbinder SP, Donnell D, Douglas JM Jr, Mayer K, Koblin B, et al. Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load. J Infect Dis 2001; 183:23-35. (Pubitemid 32043038)
27. Modjarrad K, Chamot E, Vermund SH. Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. AIDS 2008; 22:2179-2185.
28. Novitsky V,Wang R, Bussmann H, Lockman S, BaumM, Shapiro R, et al. HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the 'test-and-treat' approach to reduce HIV transmission. PLoS One 2010; 5:e10148.
29. Wright JK, Novitsky V, Brockman MA, Brumme ZL, Brumme CJ, Carlson JM, et al. Influence of Gag-protease-mediated replication capacity on disease progression in individuals recently infected with HIV-1 subtype C. J Virol 2011; 85:3996-4006.
30. Novitsky V, Woldegabriel E, Wester C, McDonald E, Rossenkhan R, Ketunuti M, et al. Identification of primary HIV-1C infection in Botswana. AIDS Care 2008; 20:806-811.
31. Novitsky V, Wang R, Kebaabetswe L, Greenwald J, Rossenkhan R, Moyo S, et al. Better control of early viral replication is associated with slower rate of elicited antiviral antibodies in the detuned enzyme immunoassay during primary HIV-1C infection. J Acquir Immune Defic Syndr 2009; 52:265-272.
32. Novitsky V, Lagakos S, Herzig M, Bonney C, Kebaabetswe L, Rossenkhan R, et al. Evolution of proviral gp120 over the first year of HIV-1 subtype C infection. Virology 2009; 383: 47-59.
33. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
34. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; 1 December 2009. http://www.aidsinfo. nih.gov/ContentFiles/AdultandAdolescentGL.pdf. [Accessed 1 November 2010].
35. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis 2008; 198:687-693.